Cingulate Therapeutics Partners with Camargo Pharmaceutical Services for Development Programs


CTX-1301 and CTX-1302 utilize FDA-approved active pharmaceutical ingredients formulated in innovative, multi-cored tablets that have target product profiles designed to deliver a rapid onset and last the entire active day while minimizing the afternoon crash and impact on sleep and appetite. Camargo is a highly experienced global strategist specializing in drug and combination device product [ ] The post Cingulate Therapeutics Partners with Camargo Pharmaceutical Services for Development Programs appeared first on STL News.
http://bit.ly/2ulu1Co

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: